Leniolisib for Immune Dysregulation in PIDs

Running, not enrolling · Phase 2

Conditions studied: Primary Immunodeficiency Disorders (PIDs)

In brief

This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.

Key facts

Study ID

NCT06549114

Run by

Pharming Technologies B.V.

People needed

12

Starts

2024-10-21

Expected to finish

2026-11-01

Last updated by the study team

2026-02-13

Who can join

Age: 12 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects 12 to 75 years of age.
• Diagnosed with a PID due to disease-causing pathogenic or likely pathogenic variant(s) in the following genes: SOCS1, PTEN, CTLA4, NFKB1 (only those variants leading to NFKB pathway activation), or FAS (germline or somatic), or diagnosed with RAS associated leukoproliferative disorder (and not juvenile myelomonocytic leukemia [JMML]) due to somatic variants in NRAS or KRAS.
• Subjects must have 1 or more of the following:
• One or more blood cytopenias related to the underlying PID defined as hemoglobin <10 g/dL, platelet count <100,000/µL, or neutrophil count <1000/µL
• Splenomegaly evident by CT imaging with craniocaudal spleen measurement >10 cm
• Lymphadenopathy evident by CT imaging with at least 1 measurable index lymph node (long axis >1.5 cm) as per Cheson methodology
• GLILD or other PID-related ILD with quantifiable CT chest imaging findings evident on baseline CT scan
• At screening, vital signs.
• Systolic blood pressure 80-139 mm Hg
• Diastolic blood pressure 50-89 mm Hg
• Pulse rate 50-110 bpm
• Oxygen saturation 93-100%
• Subjects or their legal representatives (for subjects under the age of 18 years) must be able to provide written informed consent.

You may not qualify if…

• Subject has had a successful hematopoietic stem-cell transplant (HSCT).
• Previous or concurrent use of immunosuppressive medication, such as:
• Use of an mTOR inhibitor or a PI3Kδ inhibitor within 3 weeks prior to first dosing .
• Rituximab or other B-cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months prior to first dosing.
• Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other JAK inhibitors within 3 weeks prior to first dosing.
• Corticosteroids above 25 mg prednisone or equivalent per day within 2 weeks prior to first dosing.
• Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
• Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months prior to first dosing.
• Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer) prior to first dosing.
• History of hypersensitivity to the study drug or to drugs of similar chemical classes.
• Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme P450 CYP3A.
• Current use of medications that act as BCRP, OATP1B1, and OATP1B3 substrates.
• Subject has a history or current electrocardiogram (ECG) abnormalities indicating a significant risk of safety for subjects participating in the study
• History of acquired immunodeficiency diseases, including a positive HIV test result at screening.
• Uncontrolled chronic or recurrent infectious disease (except those considered to be characteristic of a PID) or evidence of tuberculosis infection
• Any surgical or medical condition which may jeopardize the subject in case of participation in the study, or might significantly alter the absorption, distribution, metabolism, or excretion of drugs.
• A positive hepatitis B surface antigen, positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening.
• Administration of live vaccines starting from 6 weeks before first dose of study medication.
• Subject has a previous diagnosis of lymphoma within 1 year of the first dose of study medication.
• Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
• Subject has uncontrolled post-transplant lymphoproliferative disease (PTLD)-like EBV related lymphoproliferative disease.
• Donation or loss of 400 mL or more of blood within 8 weeks before the first dose.
• Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose or has a planned or expected major surgical procedure during the study period.
• Pregnant or nursing (lactating) individuals,.
• Individuals of child-bearing potential, unless they are using highly effective methods of contraception.

Where it is running

• National Institute of Health — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.